March 04, 2026 a 09:00 pm
BIIB: Analysts Ratings - Biogen Inc.
Biogen Inc. is a key player in the biotechnology sector with a focus on neurological and neurodegenerative diseases. The company has a diverse product portfolio, including multiple sclerosis treatments and biosimilars. Analysts have shown varying levels of confidence in the company's performance, particularly with concerns surrounding new drug developments and competition. The sentiment appears to be cautious yet optimistic, as reflected in recent analyst ratings.
Historical Stock Grades
In March 2026, analyst ratings for Biogen Inc. shifted slightly, with hold ratings dominating the sentiment. The ratings breakdown reveals a single strong buy and a sell rating amidst a more considerable amount of hold ratings.
| Recommendation | Count | Score Bar |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 14 | |
| Hold | 20 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
Over recent months, there has been a notable shift in the sentiment of analysts covering Biogen Inc. Key observations include:
- A steady decrease in Strong Buy ratings from 9 in 2024 to 1 in March 2026.
- An increase in Hold ratings, signifying a growing cautious sentiment.
- Buy ratings have remained relatively stable, indicating consistent optimism.
- The overall number of ratings have shown minor fluctuations.
Percentage Trends
The distribution of analyst ratings for Biogen Inc. has exhibited notable trends:
- Strong Buy ratings have significantly diminished, indicating reduced aggressive optimism.
- Percentage of Hold ratings has increased, peaking at 62.5% in March 2026.
- The trend reflects a cautious outlook, with a greater emphasis on risk management.
- Over the last year, the sentiment has shifted towards conservatism, with fewer Buy recommendations.
Latest Analyst Recommendations
Recent analyst recommendations for Biogen Inc. have predominantly maintained their previous evaluations, suggesting stable outlooks. These include:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-02-10 | Neutral | Neutral | Wedbush |
| 2026-02-09 | Equal Weight | Equal Weight | Wells Fargo |
| 2026-02-09 | Hold | Hold | Truist Securities |
| 2026-02-09 | Neutral | Neutral | JP Morgan |
| 2026-02-09 | Neutral | Neutral | Piper Sandler |
Analyst Recommendations with Change of Opinion
Some analysts have shifted their recommendations, reflecting altered perceptions of Biogen Inc.'s prospects. Notable changes include:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-12-10 | Reduce | Hold | HSBC |
| 2025-11-06 | Buy | Hold | Stifel |
| 2025-04-04 | Hold | Buy | Argus Research |
| 2025-01-02 | Neutral | Overweight | Piper Sandler |
| 2024-12-20 | Market Perform | Outperform | BMO Capital |
Interpretation
The current market assessment for Biogen Inc. suggests a period of stabilization, with analysts displaying cautious confidence. The predominance of Hold ratings indicates uncertainty amidst ongoing developments, such as drug approvals and competitive pressures. Although some downgrades reflect hesitancy, consistent Buy ratings signal underlying confidence. Stability in analyst sentiment supports a neutral market outlook with cautious optimism.
Conclusion
In conclusion, Biogen Inc.'s recent analyst ratings indicate a shift towards neutrality, reflecting cautious market sentiment. While the reduction in Strong Buy ratings suggests caution, stable Buy ratings indicate ongoing confidence in the company's potential. The observed sentiment aligns with the current sector's challenging landscape, emphasizing a balance between risk and growth opportunities. Future success will depend on the company's ability to bring new treatments to market and maintain competitive advantages.